Prevention of mother-to-child transmission

Indian Journal of Dermatology, Venereology and Leprology

Volumn 74, Issue 3, 2008, Pages 200-207

  Surjushe, Amar ^a   Maniar, Janak ^b  

^a Shri Vasantrao Naik Government Medical College   (India)

^b JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; BREAST FEEDING; CD4 LYMPHOCYTE COUNT; CESAREAN SECTION; CHILD; CHILD HEALTH CARE; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTINUOUS INFUSION; DIABETES MELLITUS; DIAGNOSTIC TEST; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TOXICITY; GENITAL TRACT INFECTION; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; IMMUNE SYSTEM; INDIA; INFANT; INFECTION CONTROL; INFECTION RATE; INFECTION RISK; LABOR; LACTIC ACIDOSIS; LIVER NECROSIS; LIVER TOXICITY; MATERNAL CARE; MATERNAL NUTRITION; MOTHER; MOTHER TO CHILD TRANSMISSION; NAUSEA; NEURAL TUBE DEFECT; NEWBORN; PATIENT COUNSELING; PATIENT EDUCATION; PRACTICE GUIDELINE; PREGNANCY; PREMATURITY; PRENATAL CARE; PUERPERIUM; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SEXUAL INTERCOURSE; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; TREATMENT INDICATION; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; VOMITING;

EID: 46349108283     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.41363     Document Type: Conference Paper

References (47)

1. Guidelines for the Prevention of Mother to Child Transmission of HIV. National AIDS Control Organisation. Available from: http://www.nacoonline.org/ guidelines/guideline_9.pdf.
2. World Health Organisation. (WHO) 2000a. Adaptation of the IMCI guidelines to take into account a high prevalence of HIV infection among children. Draft report of a consultative meeting in Durban, South Africa: August 16-18, 2000.
3. Connor EM, Sperling RS, Gelber R, Kiseleve P, Scott G, O.Sullivan MJ, et al. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med.1994;331:1173-1180.
4. Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U, et al. Prevention of vertical HIV transmission: Additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 1998;12:205-10.
5. Mandelbrot L, Le Chenadec J, Berrebi A, Bongain A, Benifla JL, Delfraissy JF, et al. Perinatal HIV-1 transmission: Interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA 1998;280:55-60.
6. Cooper ER, Charurat M, Burns DN, Blattner W, Hoff R. Trends in antiretroviral therapy and mother-infant transmission of HIV. J Acq Immune Defic Syndr 2000;24:45-7.
7. Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM. Method of feeding and transmission of HIV1 from mothers to children by 15 months of age: Prospective cohort study from Durban, South Africa. AIDS 2001;15:37987.
8. Ehrnst A, Lindgren S, Dictor M. HIV in Pregnant Women and their Offspring: Evidence for Late Transmission. Lancet 1991;338:203-7.
9. Nduati R, John G, Mbori-Ngacha D, Richardson B, Overbaugh J, Mwatha A, et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: A randomized clinical trial. JAMA 2000;283:1167-74.
10. Kapoor A, Kapoor A, Vani SN. Prevention of mother to child transmission of HIV. Indian J Pediatr 2004;71:247-51.
11. Peckham C, Gibb D. Mother-to-child transmission of the human immunodeficiency virus. N Engl J Med 1995;333: 298-302.
12. Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C, et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the Prevention of HIV Transmission from mother to infant. Nat Med 1997;3:549-52.
13. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal level of plasma HIV Type 1 RNA and the risk of Perinatal transmission. N Engl J Med 1999;341:394-402.
14. Bailey A, Newell ML, Peckham C, De Rossi A, Ehrnst A, Grosch-Wömer I, et al. Maternal viral load and vertical transmission of HIV-1: An important factor but not the only one. AIDS 1999;13:1377-85.
15. Natural history of vertically acquired human immunodeficiency virus-1 infection: The European Collaborative Study. Pediatrics 1994;94:815-9.
16. Lee MJ, Hallmark HJ, Frankel LM, Del Priore G, Maternal Syphilis and Vertical Transmission of human immunodeficiency virus Type 1. Infect Int J Obstet Gynaecol 1998;63:247-52.
17. Bulterys M, Landesman S, Burns DN, Rubinstein A, Goedert J. Sexual behavior and infection drug use during pregnancy and vertical transmission of HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:76-82.
18. Read J; for the Intl Perinatal HIV Group. Duration of rupture of membranes and vertical transmission of HIV-1: A meta-analysis from fifteen prospective cohort studies. 7th Conf Retrovirus Opportunistic Infect (Abst 659), Jan 30-Feb 2, 2000.
19. Goldenberg RL, Vermund SH, Goepfert AR, Andrews WW. Choriodecidual inflammation: A potentially preventable cause of Perinatal HIV-1 transmission. Lancet 1998;352:1927-30.
20. Prevention of Mother-to-Child Transmission of HIV in Asia: Practical Guidance for Programs June 2002, Breastfeeding, LAM, Related Complementary Feeding, and Maternal Nutrition Program.
21. Efficacy of Antiretroviral Regimens for the Prevention of Mother to Child Transmission of HIV and Some Programmatic Issues: Farley T, Buyse D, Gaillard P, Perriens J. Background documents for WHO Technical Consultation October 2000.1.
22. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Lancet 1999;353:773-80.
23. Lallemant M, Jourdain G, LeCoeur S, Kim S, Koetsawang S, Comeau AM, et al. A trial of shortened Zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. N Engl J Med 2000;343: 982-91.
24. Wiktor SZ, Ekpini E, Karon JM, Nkengason J, Maurice C, Severin ST, et al. Short course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d.Ivoire: A randomised trial. Lancet 1999;353:781-5.
25. Dabis F, Msellati P, Meda N, Welffens-Ekra C, You B, Manigart O, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d.Ivoire and Burkina Faso: A double-blind placebocontrolled multicentre trial. DITRAME Study Group. Lancet 1999;353:786-92.
26. th International AIDS Conference, Durban, South Africa, 9-14 July 2000.
27. Moodley D; on behalf of the SAINT Investigators Team. The SAINT trial: Nevirapine (NVP) versus zidovudine (ZVD) + lamivudine (3TC) in prevention of peripartum HIV transmission. Abstract LbOr 2, 13th International AIDS Conference 2000, Durban, South Africa.
28. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.
29. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States Md: AIDSinfo, US Department of Health and Human Services; 2006. Available from http://www.aidsinfo.nih.gov/guidelines. [last accessed on 2006 Oct 12].
30. Garcia-Tejedor A, Perales A, Maiques V. Protease inhibitor treatment in HIV pregnant women: Is it safe for newborns? Int J Gynaecol Obstet 2002;76:175-6.
31. Lambert JS, Watts DH, Mofenson L, Stiehm ER, Harris DR, Bethel J, et al. Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. AIDS 2000;14:1389-99.
32. Ioannidis JP, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/mL. J Infect Dis 2001;183:539-45.
33. Tuomala RE, Shapiro D, Mofenson LM, Bryson Y, Culnane M, Hughes MD, et al. Antiretroviral therapy during pregnancy and the risk of adverse outcome. N Engl J Med 2002;346:1863-70.
34. Gray J. HIV in the neonate. J Hosp Infect 1997;37:181-98.
35. American College of Obstetricians and Gynecologists. ACOG Committee Opinion number 313, September 2005. The importance of preconception care in the continuum of women.s health care. Obstet Gynecol 2005;106:665-6.
36. Elective cesarean section versus vaginal delivery in prevention of vertical HIV transmission: A randomized clinical trial. European Mode of Delivery Collaboration. Lancet 1999;353:1035-9.
37. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: A meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;34:977-87.
38. Wise J. Breast feeding safer than mixed feeding for babies of HIV mothers. Br Med J 2001;322:511-3.
39. Newburg DS, Viscidi RP, Ruff A, Yolken RH. A human milk factor inhibits binding of human immunodeficiency virus to the CD4 receptor. Pediatr Res 1991;31:22-8.
40. Stiehm ER, Vink P. Transmission of human immunodeficiency virus infection by breast-feeding. J Pediatr 1991;118:410-2.
41. Miotti PG, Taha TE, Kumwenda NI, Broadhead R, Mtimayalye LA, Van der Hoeven L, et al. HIV transmission through breastfeeding: A study in Malawi. JAMA 1999;282:744.
42. Watts DH. Management of human immunodeficiency virus infection in pregnancy. N Engl J Med 2002;346:1879-91.
43. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
44. Flys T, Nissley DV, Claasen CW, Jones D, Shi C, Guay LA, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005;192:24.
45. Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of the pediatric AIDS clinical trials group protocol 316. J Infect Dis 2002;186:181-8.
46. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, et al. Perinatal HIV prevention trial group. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-40.
47. Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998;12:2281-8.